Meeting ID: 2486 498 1264
Abstract – The development of therapeutic strategies in cancer placed great emphasis on immunotherapy. By reawakening anti-tumor immunity, remarkable responses on tumor controlling had been reported. Nevertheless, part of patients displayed “immune quiescence” with lower responses to immunotherapy. This is mostly resulted from reduced sensitivity to effector molecules and tumor microenvironment-driven T cells dysfunction. In the past hundred years, metabolic switching had been proposed as one of the hallmarks of cancer. Intriguingly, recent studies reported that “metabolic crosstalk” between infiltrating T cells and tumor cells may lead to T cell dysfunction and contribute to immunosuppressive tumor microenvironment. However, the driving force to specific metabolic activity in tumor which establish immunosuppressive microenvironment and immune evasion remain unclear. Here, I will discuss how this crosstalk can determine metabolic features in tumor cells allowing the establishment of the immunosuppressive tumor microenvironment.